Who is the CEO of Notable Labs, Ltd.?

Ms. Kaile Zagger is a business executive who currently serves as the CEO of Notable Labs, Ltd..

What is the Revenue Growth of Notable Labs, Ltd.?

Revenue growth data for Notable Labs, Ltd. is currently unavailable.

What is Notable Labs, Ltd. operating Margin?

Notable Labs, Ltd. operating margin is -307266.67% which shows how much profit NTBL earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Notable Labs, Ltd. operate?

Notable Labs, Ltd. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Notable Labs, Ltd. revenue growth?

Revenue growth data for Notable Labs, Ltd. is currently unavailable.

Notable Labs, Ltd.

NTBL•NASDAQ

HealthcareBiotechnology

$0.25

$-0.09(-27.68%)

Notable Labs, Ltd. (NTBL) Stock Overview

Explore Notable Labs, Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for NTBLStats details for NTBL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for NTBLAnalyst Recommendations details for NTBL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

CEO

Ms. Kaile Zagger

Employees

Headquarters

320 Hatch Drive, Foster City, CA

Founded

2014